Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
Immunome Inc. (IMNM) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/05/2023 8-K Investor presentation
Docs: "MORPHIMMUNE + IMMUNOME 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. and Immunome, Inc. or any person on their behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. No Representations and Warranties This presentation is being distributed solely to qualified institutional buyers and accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capability to conduct their own due diligence investiga..."
06/29/2023 8-K Investor presentation
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"Schedule A",
"Schedule A",
"Lock-Up Agreement",
"SUBSCRIPTION AGREEMENT",
"EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation , and Clay B. Siegall, Ph.D. . R E C I T A L S WHEREAS, Executive is currently the Chief Executive Officer of Morphimmune Inc., a Delaware corporation , pursuant to a certain Executive Employment Agreement dated as of January 4, 2023 ; WHEREAS, Morphimmune, the Company and Ibiza Merger Sub, Inc., a wholly owned subsidiary of Immunome , are parties to a certain Agreement and Plan of Merger and Reorganization dated as of June 29, 2023 ;    WHEREAS, upon consummation of the merger of Merger Sub into Morphimmune, as contemplated by the Merger Agreement , Morphimmune would become a wholly owned subsidiary of the Company ;   WHERE...",
"Investor Contact",
"CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. and Immunome, Inc. or any person on their behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. No Representations and Warranties This presentation is being distributed solely to qualified institutional buyers and accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capab..."
01/30/2023 8-K Investor presentation
Docs: "2 Disclaimers and Forward - Looking Statements Copyright © 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and infectious disease programs and platform, execution of our regulatory, clinical and strategic plans, therapeutic potential and benefits of our programs and anticipated upcoming milestones for our programs, as well as the timing and progress of each of the foregoing matters. Forward - looking..."
01/06/2023 8-K Investor presentation
Docs: "Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved."
11/15/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
10/18/2021 8-K Investor presentation
Docs: "Harnessing the Human Memory B Cell Response To Develop Antibody"
09/21/2021 8-K Investor presentation
Docs: "Harnessing the Human Memory B Cell Response To Develop Antibody"
07/20/2021 8-K Investor presentation
Docs: "Presentation (furnished herewith)",
"Immunome Media Contact"
03/29/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
10/26/2020 8-K Investor presentation
Docs: "Presentation (furnished herewith)"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy